Kestra Advisory Services, LLC Eagle Pharmaceuticals, Inc. Transaction History

Kestra Advisory Services, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $4,185 - $5,693	-167 Reduced 2.13%	7,672 $217,000
Q4 2022 Jan 31, 2023	BUY	$24.98 - $39.77 $2,198 - $3,499	88 Added 1.14%	7,839 $229,000
Q3 2022 Nov 01, 2022	BUY	$26.42 - $47.12 $211 - $376	8 Added 0.1%	7,751 $205 Million
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $2,723 - $3,389	66 Added 0.86%	7,743 $344,000
Q1 2022 Apr 26, 2022	SELL	$44.58 - $52.6 $5,305 - $6,259	-119 Reduced 1.53%	7,677 $379,000
Q4 2021 Jan 20, 2022	BUY	$45.82 - $56.9 $91 - $113	2 Added 0.03%	7,796 $396,000
Q3 2021 Oct 19, 2021	BUY	$43.79 - $55.78 $131 - $167	3 Added 0.04%	7,794 $434,000
Q2 2021 Jul 28, 2021	SELL	$36.86 - $44.5 $2,801 - $3,382	-76 Reduced 0.97%	7,791 $333,000
Q1 2021 May 10, 2021	BUY	$40.32 - $50.97 $14,595 - $18,451	362 Added 4.82%	7,867 $328,000
Q4 2020 Jan 20, 2021	BUY	$41.72 - $51.34 $308,728 - $379,916	7,400 Added 7047.62%	7,505 $349 Million
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $3,887 - $5,384	105 New	105 $310 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.